Duchenne Muscular Dystrophy Clinical Trial
Official title:
Optical Imaging of Dystrophic and Damaged Muscle
The purpose of this research study is to determine the potential of Optical Imaging techniques to detect muscle damage in boys with Duchenne Muscular Dystrophy and unaffected exercised muscle. Healthy subjects will undergo two different exercises in opposite forearms before any imaging techniques are performed. Boys with Duchenne Muscular Dystrophy will only undergo the imaging techniques without exercise.
The overall objective of this proposal is to validate the potential of Optical Imaging
techniques to be able to detect and quantify muscle damage in a population affected by
Duchenne Muscular Dystrophy, a muscle wasting disease, and in a healthy population that has
undergone temporal muscle damage resulting from an exercising intervention.
Duchenne Muscular Dystrophy is a relentlessly progressive degenerative muscle wasting
disease, clinically characterized by progressive muscle weakness, a loss of ambulation, and
premature mortality. Currently, no known cure exists and treatments that benefit patients
diagnosed with Duchenne Muscular Dystrophy are limited. New approaches, such as cell therapy,
gene transfer, and pharmacological interventions have shown promising results in animal
models and human studies with great potential to develop as effective therapeutic treatments.
One of the major limitations of testing these interventions; however. is the lack of
effective methods to monitor cellular and tissue changes taking place in the response to
therapy. The ability to determine cellular and tissue specific changes in damaged muscles in
real time, non-invasively, repeatedly, without exposure to any harmful radiations, with
minimal patient discomfort, and at low operating cost would enable high throughput and faster
investigation of potential therapies.
The proposed study focuses on the development of Optical Imaging technologies in the near
infrared range of wavelengths to differentiate damaged from normal muscle tissue. Near
infrared light (700 - 900 nm) has demonstrated the ability to deeply penetrate through
biological tissue, skin, and muscle without appreciable attenuation or auto-fluorescence.
The investigators anticipate that Indocyanine Green enhanced Optical Imaging can be used to
image exercise induced acute muscle damage in healthy individuals and damaged muscle and in
boys with Duchenne Muscular Dystrophy. It is anticipated that this work may fulfill the need
for imaging biomarkers that monitor and quantify cellular damage, muscle perfusion, and drug
delivery - non-invasively, using benign light, repeatedly, and in real time, with the
intention of accelerating the testing of efficacy in clinical trials for neuromuscular
disorders. The study is designed to determine the ability of Optical Imaging as a reliable,
safe, relatively inexpensive, and facile tool to detect and quantify muscle damage.
Investigators anticipate that this type of imaging modality will provide clinically useful
information for diagnostic and prognostic purposes in patients with neuromuscular diseases,
especially boys with Duchenne Muscular Dystrophy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05575648 -
Dual Task in Duchenne Muscular Dystrophy
|
N/A | |
Terminated |
NCT03907072 -
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06450639 -
An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT04335942 -
Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor
|
N/A | |
Active, not recruiting |
NCT04906460 -
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02500381 -
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
|
Phase 3 | |
Enrolling by invitation |
NCT05967351 -
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
|
Phase 3 | |
Recruiting |
NCT03067831 -
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Recruiting |
NCT01834040 -
Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Completed |
NCT02246478 -
A Study of TAS-205 for Duchenne Muscular Dystrophy
|
Phase 1 | |
Active, not recruiting |
NCT01772043 -
Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping
|
N/A | |
Terminated |
NCT01168908 -
Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT00758225 -
Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)
|
Phase 2 | |
Completed |
NCT03680365 -
Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
|
||
Recruiting |
NCT03513367 -
The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.
|
||
Recruiting |
NCT05712447 -
Duchenne Muscular Dystrophy Video Assessment Registry
|
||
Recruiting |
NCT01484678 -
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
|
||
Completed |
NCT03319030 -
Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)
|
||
Terminated |
NCT01753804 -
A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.
|
N/A | |
Completed |
NCT02530905 -
Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
|
Phase 1 |